Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors

Somatostatin receptor subtype 2 (SSTR2) has become an essential target for radionuclide therapy of neuroendocrine tumors (NETs). JR11 was introduced as a promising antagonist peptide to target SSTR2. However, due to its rapid blood clearance, a better pharmacokinetic profile is necessary for more ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Koustoulidou, Sofia, Handula, Maryana, de Ridder, Corrina, Stuurman, Debra, Beekman, Savanne, de Jong, Marion, Nonnekens, Julie, Seimbille, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503898/
https://www.ncbi.nlm.nih.gov/pubmed/36145375
http://dx.doi.org/10.3390/ph15091155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503898/
https://www.ncbi.nlm.nih.gov/pubmed/36145375
http://dx.doi.org/10.3390/ph15091155

Ejemplares similares